Drug Profile
Trastuzumab biosimilar - STC Biologics
Alternative Names: STC 101Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator STC Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Cancer in Europe (IV, Injection)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Cancer in Europe (SC, Injection)
- 01 Jul 2015 Phase-I clinical trials in Cancer in Europe (SC; IV) (STC Biologics website, June 2015) before July 2015